Fig. 5. iDuo-MM CAR-NK cells mediate superior in vivo tumor control and persist at high levels in the peripheral blood.

NSG mice (n = 28) were engrafted with 2 × 10⁵ luciferase-transduced MM.1 S cells. After 2 days, groups of mice (n = 4/group) received no treatment, daratumumab alone, 1 i.v. injection of 1 × 10⁷ backbone iNK cells or iDuo-MM CAR-NK cells, 1 injection of 1 × 10⁷ backbone iNK cells or iDuo-MM CAR-NK cells with daratumumab, three injections of 1 × 10⁷ backbone iNK cells, iDuo-MM CAR-NK cells, and expanded PBNK cells thawed from cryopreservation. Second and third effector cell injections were given at days 9 and 16 post-tumor engraftment. a Bioluminescence imaging of mice at days 2, 17, and 31. b Graphical representation of the bioluminescence data for the single effector dose arm of the study. c Peripheral blood was drawn from mice at days 22, 28, and 35 for flow cytometry analysis to determine human NK cell counts for the single effector dose arm of the study. d Representative flow cytometry plots for analysis of mouse peripheral blood in the single effector dose experiments. e Graphical representation of the bioluminescence data for the multiple effector dose arm of the study. f Analysis of human NK cell counts in the peripheral blood for the multiple effector dose arm of the study. g Representative flow cytometry plots for analysis of mouse peripheral blood in the multiple effector dose experiments. Statistical significance was determined by two-way ANOVA. All graphed data are presented mean values ± SD. Source data are provided as a Source Data file.